MTCR News and Press, Metacrine Inc. From 05/26/21

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive off...

Metracrine (MTCR) trades 10.27% higher after hours after the disclosure that its Chief Medical Officer Hubert Chen bought 3.3K shares for total transaction value of $11.8K and CEO Preston Klassen bought 20.5K shares for total transaction value of $74.7K.Last week (May...

SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data demonstrating the synerg...

Interim data from the first 60 patients with NASH on track to be reported in the fourth quarter of 2021 Enrollment continuing for up to 180 patients, with full topline results expected to be reported in the first half of 2022 SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- M...

Metacrine (MTCR): Q1 Net loss of $14.77MCash, cash equivalents and short-term investments of $84.5M.Press Release For further details see: Metacrine reports Q1 results

• Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes now expected in the fourth quarter of 2021 • Interim data from the Phase 2a trial of MET642 in NASH patients on track to be reported in the...

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive off...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.08. This new low was reached on above average trading volume as 264,000 shares traded hands, while the average 30-day volume is approximately 92,000 shares. Metacrine Inc is a clinical-stage biopharmaceutical ...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded today at $4.02, breaking its 52-week low. Approximately 264,000 shares have changed hands today, as compared to an average 30-day volume of 79,000 shares. Over the past year, Metacrine Inc. has traded in a range of $4.02 to $16.19 and is now ...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.72. So far today approximately 264,000 shares have been exchanged, as compared to an average 30-day volume of 79,000 shares. Potential upside of 9.3% exists for Metacrine Inc., based on a current level of $4.7...